Subscribe To
Longeveron to report third quarter 2023 results and provide corporate update on november 10, 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...
November 3, 2023, 12:00 pm
Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion
On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic...
November 2, 2023, 8:29 pm
Zyversa therapeutics announces publication in molecular neurobiology reinforcing data demonstrating that inflammasome asc inhibitor ic 100 attenuates the inflammatory response causing neuronal damage
Molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the pathogenesis of multiple sclerosis (“MS”) b...
November 1, 2023, 12:07 pm
Update — scilex holding company files emergency motion in the united states bankruptcy court for the southern district of texas for entry of an order compelling the production of books and records fro
PALO ALTO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-gene...
October 27, 2023, 7:38 pm
Mallinckrodt to present data on terlivaz® (terlipressin) for injection in adult patients with hepatorenal syndrome (hrs) at the american college of gastroenterology (acg) annual scientific meeting
– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients'...
October 22, 2023, 3:05 pm
Ipo update: chromocell therapeutics seeks $8.7 million in micro-ipo
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic...
October 19, 2023, 5:31 pm
Why ardelyx stock popped today
Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease d...
October 18, 2023, 4:31 pm
Zyversa therapeutics announces a publication in the peer-reviewed journal, aging, linking inflammasome nlrp3 activation with age-related structural changes in the kidney and reduced kidney function
chronic kidney disease is most common in people 65 years and older. NLRP3 inflammasomes signaling in th...
October 18, 2023, 11:05 am
Ardelyx wins long battle for fda approval of kidney-disease treatment
Ardelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with ...
October 17, 2023, 7:24 pm
Ocean biomedical (nasdaq: ocea) announces enrollment of patients for phase 1b study for chronic hepatitis b treatment in 50-50 joint venture with virion therapeutics
Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the deve...
October 17, 2023, 12:01 pm
Terns pharmaceuticals announces global phase 1 clinical trial design of tern-701 for the treatment of chronic myeloid leukemia
Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner’s ongoing Phase 1 trial in ...
October 16, 2023, 12:05 pm
: novo nordisk to buy hypertension treatment from for $1.3 billion from kbp biosciences
Novo Nordisk A/S NVODK:NOVO.B said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is...
October 16, 2023, 11:11 am
Lyra therapeutics announces appointment of ronan o’brien as chief legal officer
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotec...
October 16, 2023, 11:00 am
Mineralys therapeutics announces upcoming poster presentations at two scientific conferences in november 2023
Late-breaking poster presentation at ASN’s Kidney Week 2023 – – –Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13,...
October 13, 2023, 8:10 pm
Longeveron announces closing of $4 million registered direct offering priced at-the-market under nasdaq rules
MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...
October 13, 2023, 8:05 pm
Why shares of prokidney were dropping thursday
ProKidney focuses on therapies to treat chronic kidney disease (CKD). One of its top shareholders sold ...
October 12, 2023, 3:05 pm
Claudia goldin’s nobel prize win is a victory for women in economics – and the field as a whole
By Veronika Dolar, SUNY Old Westbury Economic history has long been chronicled through a male lens, emp...
October 12, 2023, 1:36 pm
Virios therapeutics to present at the thinkequity conference on thursday, october 19, 2023
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company fo...
October 12, 2023, 11:05 am
Davita says news of ozempic's potential in treating kidney disease may have only limited impact for patients, says further studies will be needed
Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatmen...
October 12, 2023, 8:43 am
Davita says ozempic's early success in kidney trial to have 'limited application'
Dialysis firm DaVita said on Thursday it believes that early success of Novo Nordisk's diabetes drug Ozempic in kidney disease trial will have "limite...
October 12, 2023, 8:41 am